[Bloomberg News]Stand Up Therapeutics and VectorBuilder Announced the …
Summary: South Korean-based Stand Up Therapeutics Co., Ltd. is a gene therapy
firm for paralysed individuals with spinal cord damage. Stand Up Therapeutics
said that it had inked a contract with VectorBuilder Inc., a global leader in
gene delivery technologies, to produce a GMP-grade gene delivery system.
Seoul, South Korea--(Newsfile Corp. - January 11, 2023) - Stand Up
Therapeutics Co., Ltd. has emerged as a gene therapy firm where Stand Up
Therapeutics and VectorBuilder announced the initiative to supply the initial
paraplegic patient's gene therapy materials. According to Stand Up
Therapeutics, VectorBuilder will create and distribute gene therapy products
designed by Stand Up Therapeutics in the future under this arrangement. The
objective is to control the global market.
Chief Scientist of VectorBuilder Bruce Lahn stated, "VectorBuilder is
particularly interested in Stand Up Therapeutics' gene therapy for the global
treatment of paralysis. As a global pioneer in the design and GMP manufacture
of gene delivery vectors, I am hopeful that VectorBuilder will have the
opportunity to sell this product to Stand Up for patients worldwide."
VectorBuilder is the world's largest provider of customized vectors for viral
and non-viral gene delivery, operating as a multinational corporation with
offices in North America, Europe, China, Japan, Korea, Australia, and Israel.
The company is headquartered in Chicago, Illinois, and has offices in North
America, Europe, China, Japan, Korea, Australia, and Israel. Currently, more
than 80,000 bespoke vectors are created each year for scholars all around the
world. VectorBuilder has GMP facilities for gene delivery systems and provides
gene therapy products and delivery systems to tens of thousands of
institutions and over 50,000 customers, including the world's top
pharmaceutical corporations and universities. VectorBuilder provides gene
therapy items and delivery mechanisms.
Dr. Junsang Yoo, the chief executive officer of Stand Up Therapeutics, stated,
"Stand Up Therapeutics is the only company in the world with the technology to
treat paralysed patients as a result of spinal cord damage utilising its own
developed direct lineage reprogramming technique (STUP-001)." The members of
Stand Up Therapeutics are devoting their whole efforts to the development of a
treatment for people with paralysis caused by catastrophic damage. Also,
"Stand Up Therapeutics hopes to develop treatments for Parkinson's disease
(STUP-002), stroke (STUP-003), spinal stenosis (STUP-004), and myocardial
infarction (STUP-005) in the future using the direct cross-differentiation
STUP-001, a gene therapy treatment for spinal cord injury (SCI), will enter
the IIT Clinical phase I/IIa research in the first quarter of 2023 with four
Stand Up Therapeutics
About Stand Up Therapeutics Co., Ltd.
Using cutting-edge technologies, Stand Up Therapeutics Co., Ltd. develops gene
therapies for nerve cell regeneration by transforming fibroblasts into motor
neurons in vivo. Stand Up Therapeutics intends to deploy direct lineage
reprogramming technology to treat mild and severely paralysed patients, who
make up approximately 1.9% of the world's population and have suffered spinal
cord and brain injuries. Stand Up Therapeutics will expand its pipeline
through the development of safer and more effective direct reprogramming
techniques and gene therapy.